Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 338, b2270

Effect of Withdrawal of Co-Proxamol on Prescribing and Deaths From Drug Poisoning in England and Wales: Time Series Analysis

Affiliations

Effect of Withdrawal of Co-Proxamol on Prescribing and Deaths From Drug Poisoning in England and Wales: Time Series Analysis

Keith Hawton et al. BMJ.

Abstract

Objective: To assess the effect of the UK Committee on Safety of Medicines' announcement in January 2005 of withdrawal of co-proxamol on analgesic prescribing and poisoning mortality.

Design: Interrupted time series analysis for 1998-2007.

Setting: England and Wales.

Data sources: Prescribing data from the prescription statistics department of the Information Centre for Health and Social Care (England) and the Prescribing Services Unit, Health Solutions Wales (Wales). Mortality data from the Office for National Statistics.

Main outcome measures: Prescriptions. Deaths from drug poisoning (suicides, open verdicts, accidental poisonings) involving single analgesics.

Results: A steep reduction in prescribing of co-proxamol occurred in the post-intervention period 2005-7, such that number of prescriptions fell by an average of 859 (95% confidence interval 653 to 1065) thousand per quarter, equating to an overall decrease of about 59%. Prescribing of some other analgesics (co-codamol, paracetamol, co-dydramol, and codeine) increased significantly during this time. These changes were associated with a major reduction in deaths involving co-proxamol compared with the expected number of deaths (an estimated 295 fewer suicides and 349 fewer deaths including accidental poisonings), but no statistical evidence for an increase in deaths involving either other analgesics or other drugs.

Conclusions: Major changes in prescribing after the announcement of the withdrawal of co-proxamol have had a marked beneficial effect on poisoning mortality involving this drug, with little evidence of substitution of suicide method related to increased prescribing of other analgesics.

Conflict of interest statement

Competing interests: KH and SS presented evidence to the MHRA committee that evaluated co-proxamol.

Figures

None
Fig 1 Prescriptions for analgesics dispensed in England and Wales, 1998-2007.
None
Fig 2 Mortality in England and Wales from analgesic poisoning (suicide and open verdicts), 1998-2007, for people aged 10 years and over (substances taken alone, with or without alcohol)

Similar articles

See all similar articles

Cited by 19 PubMed Central articles

See all "Cited by" articles

References

    1. Simkin S, Hawton K, Sutton L, Gunnell D, Bennewith O, Kapur N. Co-proxamol and suicide: a review to inform initiatives to prevent the continuing toll of overdose deaths. Q J Med 2005;98:159-70. - PubMed
    1. Hawton K, Simkin S, Deeks JJ. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self-poisonings. BMJ 2003;326:1006-8. - PMC - PubMed
    1. Drug and Therapeutics Bulletin. Distalgesic and its equivalents: time for action. DTB 1983;21:17-9. - PubMed
    1. Bateman DN, Afshari R. Licence needs to be changed. BMJ 2003;327:287. - PMC - PubMed
    1. Hawton K, Simkin S, Gunnell D, Sutton L, Bennewith O, Turnbull P, et al. A multicentre study of co-proxamol poisoning suicides based on coroners’ records in England. Br J Clin Pharmacol 2005;59:207-12. - PMC - PubMed

Publication types

MeSH terms

Feedback